Skip to main content
Top
Published in: Archives of Osteoporosis 1/2018

01-12-2018 | Original Article

Calcitriol treatment in patients with low vitamin D levels

Authors: Refik Tanakol, Nurdan Gül, Ayşe Kubat Üzüm, Ferihan Aral

Published in: Archives of Osteoporosis | Issue 1/2018

Login to get access

Abstract

Summary

The aim of the the study is to compare the effects of cholecalciferol and calcitriol on bone mineral metabolism in women with vitamin D deficiency. Calcitriol was associated with a significant increase in bone mineral density at the lumbar spine in patients with low vitamin D levels.

Purpose/introduction

Active vitamin D analogs may have larger impact in decreasing bone loss and fracture rate compared to cholecalciferol in osteoporosis. However, their effects in the treatment of vitamin D deficiency compared to cholecalciferol are not clear. The aim of the present study is to compare the effects of cholecalciferol and calcitriol on bone mineral metabolism and bone mineral density in pre- and postmenopausal women with vitamin D deficiency.

Methods

This was a 6-month prospective, open-label, controlled clinical trial. Eligible 120 participants were pre- and postmenopausal women diagnosed with vitamin D deficiency. Forty-three subjects (group 1) received 1000 IU of cholecalciferol and 1 g of calcium daily. The other 77 subjects (group 2) received 0.5 μg calcitriol in addition to 400 IU of cholecalciferol and 1 g of calcium daily.

Results

Oral vitamin D supplementation did not increase bone mineral density after 6 months of intervention in group 1. On the other hand, bone mineral density at the lumbar spine increased from 0.809 ± 0.172 to 0.848 ± 0.161 g/cm2 in group 2 patients (p < 0.017 vs baseline).

Conclusions

Oral daily calcitriol was associated with a significant increase in bone mineral density at the lumbar spine in patients with low vitamin D, elevated PTH, and osteoporosis.
Literature
2.
go back to reference Li X, Liao L, Yan X, Huang G, Lin J, Lei M, Wang X, Zhou Z (2009) Protective effects of 1-α-hydroxyvitamin D3 on residual beta-cell function in adult-onset latent autoimmune diabetes (LADA). Diabetes Metab Res Rev 25:411–416CrossRef Li X, Liao L, Yan X, Huang G, Lin J, Lei M, Wang X, Zhou Z (2009) Protective effects of 1-α-hydroxyvitamin D3 on residual beta-cell function in adult-onset latent autoimmune diabetes (LADA). Diabetes Metab Res Rev 25:411–416CrossRef
3.
go back to reference Chapuy MC, Pamphile R, Paris E, Kempf C, Schlichting M, Arnaud S, Garnero P, Garnero P, Meunier PJ (2002) Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int 13(3):257–264CrossRef Chapuy MC, Pamphile R, Paris E, Kempf C, Schlichting M, Arnaud S, Garnero P, Garnero P, Meunier PJ (2002) Combined calcium and vitamin D3 supplementation in elderly women: confirmation of reversal of secondary hyperparathyroidism and hip fracture risk: the Decalyos II study. Osteoporos Int 13(3):257–264CrossRef
4.
go back to reference Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 282(14):1344–1352CrossRef Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis. JAMA 282(14):1344–1352CrossRef
5.
go back to reference Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD, and for the oral ibandronate osteoporosis vertebral fracture trial in North America and Europe (Bone) (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19(8):1241–1249CrossRef Chesnut CH, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD, and for the oral ibandronate osteoporosis vertebral fracture trial in North America and Europe (Bone) (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19(8):1241–1249CrossRef
6.
go back to reference Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, Lorenc R, Pors-Nielsen S, De Vernejoul MC, Roces A, Reginster JY (2002) Strontium ranelate: dose dependent effects in established postmenopausal vertebral osteoporosis- a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 87:2060–2066PubMed Meunier PJ, Slosman DO, Delmas PD, Sebert JL, Brandi ML, Albanese C, Lorenc R, Pors-Nielsen S, De Vernejoul MC, Roces A, Reginster JY (2002) Strontium ranelate: dose dependent effects in established postmenopausal vertebral osteoporosis- a 2-year randomized placebo controlled trial. J Clin Endocrinol Metab 87:2060–2066PubMed
7.
go back to reference Lau KH, Baylink DJ (1999) Vitamin D therapy of osteoporosis: plain vitamin D therapy versus active vitamin D analog (D-hormone) therapy. Calcif Tissue Int 65:295–306CrossRef Lau KH, Baylink DJ (1999) Vitamin D therapy of osteoporosis: plain vitamin D therapy versus active vitamin D analog (D-hormone) therapy. Calcif Tissue Int 65:295–306CrossRef
8.
go back to reference Bischoff-Ferrari HA, Borchers M, Gudat F, Dürmüller U, Stahelin HB, Dick W (2004) Vitamin D receptor expression in human muscle tissue decreases with age. J Bone Miner Res 19:265–269CrossRef Bischoff-Ferrari HA, Borchers M, Gudat F, Dürmüller U, Stahelin HB, Dick W (2004) Vitamin D receptor expression in human muscle tissue decreases with age. J Bone Miner Res 19:265–269CrossRef
9.
go back to reference Papadimitropoulos E, Wells G, Shea B (2002) Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 23:560–569CrossRef Papadimitropoulos E, Wells G, Shea B (2002) Meta-analysis of the efficacy of vitamin D treatment in preventing osteoporosis in postmenopausal women. Endocr Rev 23:560–569CrossRef
10.
go back to reference Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R (2005) Estimates of optimal vitamin D status. Osteoporos Int 16:713–716CrossRef Dawson-Hughes B, Heaney RP, Holick MF, Lips P, Meunier PJ, Vieth R (2005) Estimates of optimal vitamin D status. Osteoporos Int 16:713–716CrossRef
11.
go back to reference Genant HK, Jergas M, Palermo L et al (1996) Coomparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. J Bone Miner Res 11:984–996CrossRef Genant HK, Jergas M, Palermo L et al (1996) Coomparison of semiquantitative visual and quantitative morphometric assessment of prevalent and incident vertebral fractures in osteoporosis. J Bone Miner Res 11:984–996CrossRef
12.
go back to reference World Medical Association Declaration of Helsinki (2000) Ethical principles for medical research involving human subjects. JAMA 284:3043–3045CrossRef World Medical Association Declaration of Helsinki (2000) Ethical principles for medical research involving human subjects. JAMA 284:3043–3045CrossRef
13.
go back to reference Zhang H, Huang Q, Gu J, HU W, Liu Y, Hu Y, Zhang Z (2012) Comparison of the effects of cholecalciferol and calcitriol on calcium metabolism and bone turnover in Chinese postmenopausal women with vitamin D insufficiency. Acta Pharmacol Sin 33(4):490–495CrossRef Zhang H, Huang Q, Gu J, HU W, Liu Y, Hu Y, Zhang Z (2012) Comparison of the effects of cholecalciferol and calcitriol on calcium metabolism and bone turnover in Chinese postmenopausal women with vitamin D insufficiency. Acta Pharmacol Sin 33(4):490–495CrossRef
14.
go back to reference Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson Hughes B (2005) Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 293:2257–2264CrossRef Bischoff-Ferrari HA, Willett WC, Wong JB, Giovannucci E, Dietrich T, Dawson Hughes B (2005) Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA 293:2257–2264CrossRef
15.
go back to reference Binkley N, Novotny R, Krueger D, Kawahara TN, Daida YG, Gemar D, Lensmeyer GL, Hollis BW, Drezner MK (2007) J. Low vitamin D status despite abundant sun exposure. J Clin Endocrinol Metab 92:2130–2135CrossRef Binkley N, Novotny R, Krueger D, Kawahara TN, Daida YG, Gemar D, Lensmeyer GL, Hollis BW, Drezner MK (2007) J. Low vitamin D status despite abundant sun exposure. J Clin Endocrinol Metab 92:2130–2135CrossRef
16.
go back to reference Holick MF, Siris ES, Binkley N, Beard MK, Khan A, Katzer J, Petruschek RA, Chen E, dePapp AE (2005) Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 90: 3215–24CrossRef Holick MF, Siris ES, Binkley N, Beard MK, Khan A, Katzer J, Petruschek RA, Chen E, dePapp AE (2005) Prevalence of Vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 90: 3215–24CrossRef
17.
go back to reference Seeman E, Delmas PD (2006) Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 354:2250–2261CrossRef Seeman E, Delmas PD (2006) Bone quality-the material and structural basis of bone strength and fragility. N Engl J Med 354:2250–2261CrossRef
18.
go back to reference Ringe JD, Schacht E (2004) Prevention and therapy of osteoporosis: the roles of plain vitamin D and alfacalcidol. Rheumatol Int 24:189–197CrossRef Ringe JD, Schacht E (2004) Prevention and therapy of osteoporosis: the roles of plain vitamin D and alfacalcidol. Rheumatol Int 24:189–197CrossRef
19.
go back to reference Tsukamoto Y, Watanabe T, Nakagami T, Morishita K (2003) Effect of treatment with oral calcitriol on calcium metabolism and fasting serum 25OH-or 1,25(OH)2 vitamin D level in Japanese postmenopausal women. Endocr J 50:681–687CrossRef Tsukamoto Y, Watanabe T, Nakagami T, Morishita K (2003) Effect of treatment with oral calcitriol on calcium metabolism and fasting serum 25OH-or 1,25(OH)2 vitamin D level in Japanese postmenopausal women. Endocr J 50:681–687CrossRef
20.
go back to reference Gurlek A, Pittelkow MR, Kumar R (2002) Modulation of growth factor/cytokine synthesis and signalling by 1alpha,25dihydroxyvitamin D3: implications in cell growth and differentiation. Endocr Rev 23:763–786CrossRef Gurlek A, Pittelkow MR, Kumar R (2002) Modulation of growth factor/cytokine synthesis and signalling by 1alpha,25dihydroxyvitamin D3: implications in cell growth and differentiation. Endocr Rev 23:763–786CrossRef
21.
go back to reference Sibata T, Shira-Ishi A, Sato T, Masaki T, Sasaki A, Masuda Y et al (2002) Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in bone marrow. J Bone Miner Res 17:622–629CrossRef Sibata T, Shira-Ishi A, Sato T, Masaki T, Sasaki A, Masuda Y et al (2002) Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in bone marrow. J Bone Miner Res 17:622–629CrossRef
22.
go back to reference Dobnig H (2011) A review of the health consequences of the vitamin D deficiency pandemic. J Neurol Sci 311(1–2):15–18CrossRef Dobnig H (2011) A review of the health consequences of the vitamin D deficiency pandemic. J Neurol Sci 311(1–2):15–18CrossRef
23.
go back to reference Clements MR, Davies M, Hayes ME, Hickey CD, Lumb GA, Mawer EB et al (1992) The role of 1,25-dihydroxyvitamin D in the mechanism of acquired vitamin D deficiency. Clin Endocrinol. Oxf 37:17–27 Clements MR, Davies M, Hayes ME, Hickey CD, Lumb GA, Mawer EB et al (1992) The role of 1,25-dihydroxyvitamin D in the mechanism of acquired vitamin D deficiency. Clin Endocrinol. Oxf 37:17–27
24.
go back to reference Halloran BP, Bikle DD, Levens MJ, Castro ME, Globus RK, Holton E (1986) Chronic 1,25-dihydroxyvitamin D3 administration in the rat reduces the serum conentration of 25-hydroxyvitamin D by increasing metabolic clearance rate. J Clin Invest 78:622–628CrossRef Halloran BP, Bikle DD, Levens MJ, Castro ME, Globus RK, Holton E (1986) Chronic 1,25-dihydroxyvitamin D3 administration in the rat reduces the serum conentration of 25-hydroxyvitamin D by increasing metabolic clearance rate. J Clin Invest 78:622–628CrossRef
25.
go back to reference Harwood RH, Sahota O, Gaynor K, Masud T, Hosking DJ (2004) A randomised controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: the Nottingham neck of femur (NoNOF) study. Age Ageing 33:45–51CrossRef Harwood RH, Sahota O, Gaynor K, Masud T, Hosking DJ (2004) A randomised controlled comparison of different calcium and vitamin D supplementation regimens in elderly women after hip fracture: the Nottingham neck of femur (NoNOF) study. Age Ageing 33:45–51CrossRef
26.
go back to reference Richy F, Ethgen O, Bruyere O, Reginster J-Y (2004) Efficacy of alfacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 15(4):301–310CrossRef Richy F, Ethgen O, Bruyere O, Reginster J-Y (2004) Efficacy of alfacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Osteoporos Int 15(4):301–310CrossRef
27.
go back to reference Gallagher JC (2004) The effects of calcitriol on falls and fractures and physical performance tests. J Steroid Biochem Mol Biol 89-90:497–501CrossRef Gallagher JC (2004) The effects of calcitriol on falls and fractures and physical performance tests. J Steroid Biochem Mol Biol 89-90:497–501CrossRef
28.
go back to reference Schacht E, Richy F, Reginster J-Y (2005) The therapeutic effects of alfacalcidiol on bone strength, muscle metabolism and prevention of falls and fractures. J Musculoskelet Neuronal Interact 5(3):273–284PubMed Schacht E, Richy F, Reginster J-Y (2005) The therapeutic effects of alfacalcidiol on bone strength, muscle metabolism and prevention of falls and fractures. J Musculoskelet Neuronal Interact 5(3):273–284PubMed
29.
go back to reference Richy F, Dukas L, Schacht E (2008) Differential effects of D-hormone analogus and native vitamin D on the risk of falls: a comparative meta-analysis. Calcif Tissue Int 82:102–107CrossRef Richy F, Dukas L, Schacht E (2008) Differential effects of D-hormone analogus and native vitamin D on the risk of falls: a comparative meta-analysis. Calcif Tissue Int 82:102–107CrossRef
30.
go back to reference Shane E, Adesso V, Namerow PB, McMahon DJ, Lo SH, Staron RB, Zucker M, Pardi S, Maybaum S, Mancini D (2004) Alendronate or calcitriol and prevention of bone loss after cardiac transplantation. N Engl J Med 350(8):767–776CrossRef Shane E, Adesso V, Namerow PB, McMahon DJ, Lo SH, Staron RB, Zucker M, Pardi S, Maybaum S, Mancini D (2004) Alendronate or calcitriol and prevention of bone loss after cardiac transplantation. N Engl J Med 350(8):767–776CrossRef
31.
go back to reference Frediani B, Allegri A, Bisohno S, Marcolongo R (1998) Effects combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis. Two years of continuous treatment. Clin Drug Invest 14:235–244CrossRef Frediani B, Allegri A, Bisohno S, Marcolongo R (1998) Effects combined treatment with calcitriol plus alendronate on bone mass and bone turnover in postmenopausal osteoporosis. Two years of continuous treatment. Clin Drug Invest 14:235–244CrossRef
32.
go back to reference Hermann M, Widmann T, Colaianni G, Colucci S, Zallone A, Hermann W (2005) Increased osteoclastic activity in the presence of increased homocysteine concentrations. Clin Chem 51:2348–2353CrossRef Hermann M, Widmann T, Colaianni G, Colucci S, Zallone A, Hermann W (2005) Increased osteoclastic activity in the presence of increased homocysteine concentrations. Clin Chem 51:2348–2353CrossRef
33.
go back to reference Hubmacher D, Sabatier L, Annis DS, Mosher DF (2011) Reinhardt DP. Homocysteine modifies structural and functional properties of fibronectin and interferes with the fibronectin-fibrillin-1 interaction. Biochemistry 50:5322–5332CrossRef Hubmacher D, Sabatier L, Annis DS, Mosher DF (2011) Reinhardt DP. Homocysteine modifies structural and functional properties of fibronectin and interferes with the fibronectin-fibrillin-1 interaction. Biochemistry 50:5322–5332CrossRef
34.
go back to reference Calo L, Castrignano R, Davis PA, Carraro G, Pagnin E, Giannini S, Semplicini A, D’Angelo AA (2000) Role of insulin-like growth factor-I in primary osteoporosis: a correlative study. J Endocrinol Investig 23:223–227CrossRef Calo L, Castrignano R, Davis PA, Carraro G, Pagnin E, Giannini S, Semplicini A, D’Angelo AA (2000) Role of insulin-like growth factor-I in primary osteoporosis: a correlative study. J Endocrinol Investig 23:223–227CrossRef
35.
go back to reference Boonen S, Mohan S, Dequeker J, Aerssens J, Vanderschueren D, Verbeke G, Broos P, Bouillon R, Baylink DJ (1999) Down-regulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein (BP)-3 and IGFBP-5) in age related (type II) femoral neck osteoporosis. J Bone Miner Res 14:2150–2158CrossRef Boonen S, Mohan S, Dequeker J, Aerssens J, Vanderschueren D, Verbeke G, Broos P, Bouillon R, Baylink DJ (1999) Down-regulation of the serum stimulatory components of the insulin-like growth factor (IGF) system (IGF-I, IGF-II, IGF binding protein (BP)-3 and IGFBP-5) in age related (type II) femoral neck osteoporosis. J Bone Miner Res 14:2150–2158CrossRef
36.
go back to reference Li J, Jih D, Fu S, Mei G, Zhou J, Lei L, Yu B, Wang G (2013) Insulin -like growth factor binding protein-3 modulates osteoblast differentiation via interaction with vitamin D receptor. Biochem Biophys Res Commun 436:632–637CrossRef Li J, Jih D, Fu S, Mei G, Zhou J, Lei L, Yu B, Wang G (2013) Insulin -like growth factor binding protein-3 modulates osteoblast differentiation via interaction with vitamin D receptor. Biochem Biophys Res Commun 436:632–637CrossRef
Metadata
Title
Calcitriol treatment in patients with low vitamin D levels
Authors
Refik Tanakol
Nurdan Gül
Ayşe Kubat Üzüm
Ferihan Aral
Publication date
01-12-2018
Publisher
Springer London
Published in
Archives of Osteoporosis / Issue 1/2018
Print ISSN: 1862-3522
Electronic ISSN: 1862-3514
DOI
https://doi.org/10.1007/s11657-018-0529-2

Other articles of this Issue 1/2018

Archives of Osteoporosis 1/2018 Go to the issue